Skip to content
DataLookout
Menu

NCT06787612

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 25 versions: 25 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 12 words
    • Enrollment increased: 297 → 397 participants
    • Trial arms changed: 6 → 10
    • Site details revised at 3 of 56 sites
  2. Minor Study sites: 55 to 56v24
  3. Minor Enrollment increased: 220 → 297 participantsv23 Show 5 more changesShow less
    • Primary and study completion moved earlier from Oct 30, 2028 to Jun 30, 2028
    • Trial arms changed: 5 → 6
    • Study sites: 54 to 55
    • Interventions: Bevacizumab (Drug), Cemiplimab (Drug), Fianlimab (Drug), PLD (Drug), Sarilumab (Drug), Ubamatamab (Drug) to Bevacizumab (Drug), Cemiplimab (Drug), Fianlimab (Drug), PLD (Drug), REGN10597 (Drug), Sarilumab (Drug), Ubamatamab (Drug)
    • Secondary endpoints: 16 to 19
  4. Minor Study sites: 53 to 54v22
  5. Minor Study sites: 52 to 53v21
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites: 50 to 52v20
  2. Minor Site details revised at 1 of 50 sitesv19
  1. Minor Trial sites expanded: 47 → 50 locationsv18
  2. Notable Eligibility criteria expanded, about 22 words
    • Study sites: 44 to 47
    • Primary and study completion dates: Dec 7, 2028 to Oct 30, 2028
    • Secondary endpoints revised (16)
    v17
  3. Minor Study sites: 43 to 44v16
  4. Minor Study sites: 41 to 43v15
  5. Minor Study sites: 36 to 41v14
  6. Minor Study sites: 34 to 36v13
  7. Minor Study sites: 30 to 34v12
  8. Minor Study sites: 29 to 30v11
  9. Minor Study sites: 24 to 29v10
  10. Minor Study sites: 22 to 24v9
  11. Minor Study sites: 19 to 22v8
  12. Minor Study sites: 16 to 19v7
  13. Minor Study sites: 9 to 16v6
  14. Minor Study sites: 6 to 9v5
  15. Minor Study sites: 1 to 6v4
  16. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 23, 2025 to May 28, 2025
    v3
  17. Notable Primary and study completion dates: Apr 30, 2028 to Dec 7, 2028
    • Start date: May 1, 2025 to May 23, 2025
    v2
  18. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment
Timeframe: Up to 3 years

Secondary (19)

Cancer Antigen (CA) -125 response by Gynecologic Cancer Intergroup (GCIG) Criteria
Complete Response (CR) rate by RECIST 1.1
Disease Control Rate (DCR) by RECIST 1.1
Duration of Response (DOR) by RECIST 1.1
Progression-Free Survival (PFS) by RECIST 1.1
Show 14 moreShow less
Occurrence of Grade ≥ 2 Cytokine Release Syndrome (CRS) by Lee criteria
Treatment-Emergent Adverse Events (TEAEs) by Common Terminology Criteria for Adverse Events (CTCAE) v5.0
TEAEs by Lee criteria
Concentration of ubamatamab in serum
Concentration of fianlimab in serum
Concentration of REGN10597 in serum
Occurrence of Anti-Drug Antibodies (ADA) to ubamatamab
Magnitude of ADA to ubamatamab
Occurrence of ADA to fianlimab
Magnitude of ADA to fianlimab
Occurrence of ADA to cemiplimab
Magnitude of ADA to cemiplimab
Occurrence of ADA to REGN10597
Magnitude of ADA to REGN10597

Arms and interventions

Arm A1Experimental
Arm A2Experimental
Arm BExperimental
Arm CExperimental
Arm DExperimental
Arms E1/E2Experimental
Arm FaExperimental
Arm GaExperimental
Arm FbExperimental
Arm GbExperimental

Drugs: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597

Sites

56 sites in 5 countries

United States 21, Turkey (Türkiye) 12, South Korea 10, Taiwan 7, Canada 6